508 related articles for article (PubMed ID: 29356953)
1. The use of PIPAC (pressurized intraperitoneal aerosol chemotherapy) in gynecological oncology: a statement by the "Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR)", the Swiss and Austrian AGO, and the North-Eastern German Society of Gynaecologic Oncology.
Dueckelmann AM; Fink D; Harter P; Heinzelmann V; Marth C; Mueller M; Reinthaller A; Tamussino K; Wimberger P; Sehouli J
Arch Gynecol Obstet; 2018 Apr; 297(4):837-846. PubMed ID: 29356953
[TBL] [Abstract][Full Text] [Related]
2. Concentrations of cisplatin and doxorubicin in ascites and peritoneal tumor nodules before and after pressurized intraperitoneal aerosol chemotherapy (PIPAC) in patients with peritoneal metastasis.
Tempfer CB; Hilal Z; Dogan A; Petersen M; Rezniczek GA
Eur J Surg Oncol; 2018 Jul; 44(7):1112-1117. PubMed ID: 29753612
[TBL] [Abstract][Full Text] [Related]
3. Activity of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with cisplatin and doxorubicin in women with recurrent, platinum-resistant ovarian cancer: preliminary clinical experience.
Tempfer CB; Celik I; Solass W; Buerkle B; Pabst UG; Zieren J; Strumberg D; Reymond MA
Gynecol Oncol; 2014 Feb; 132(2):307-11. PubMed ID: 24275155
[TBL] [Abstract][Full Text] [Related]
4. Multicenter comprehensive methodological and technical analysis of 832 pressurized intraperitoneal aerosol chemotherapy (PIPAC) interventions performed in 349 patients for peritoneal carcinomatosis treatment: An international survey study.
Nowacki M; Alyami M; Villeneuve L; Mercier F; Hubner M; Willaert W; Ceelen W; Reymond M; Pezet D; Arvieux C; Khomyakov V; Lay L; Gianni S; Zegarski W; Bakrin N; Glehen O
Eur J Surg Oncol; 2018 Jul; 44(7):991-996. PubMed ID: 29526367
[TBL] [Abstract][Full Text] [Related]
5. Safety and feasibility of pressurized intraperitoneal aerosol chemotherapy (PIPAC) associated with systemic chemotherapy: an innovative approach to treat peritoneal carcinomatosis.
Robella M; Vaira M; De Simone M
World J Surg Oncol; 2016 Apr; 14():128. PubMed ID: 27125996
[TBL] [Abstract][Full Text] [Related]
6. A phase I, single-arm, open-label, dose escalation study of intraperitoneal cisplatin and doxorubicin in patients with recurrent ovarian cancer and peritoneal carcinomatosis.
Tempfer CB; Giger-Pabst U; Seebacher V; Petersen M; Dogan A; Rezniczek GA
Gynecol Oncol; 2018 Jul; 150(1):23-30. PubMed ID: 29743140
[TBL] [Abstract][Full Text] [Related]
7. Initial experience of pressurized intraperitoneal aerosol chemotherapy (PIPAC) in a French hyperthermic intraperitoneal chemotherapy (HIPEC) expert center.
Ceribelli C; Debs T; Chevallier A; Piche MA; Bereder JM
Surg Endosc; 2020 Jun; 34(6):2803-2806. PubMed ID: 32166545
[TBL] [Abstract][Full Text] [Related]
8. Quality of life of patients with end-stage peritoneal metastasis treated with Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC).
Odendahl K; Solass W; Demtröder C; Giger-Pabst U; Zieren J; Tempfer C; Reymond MA
Eur J Surg Oncol; 2015 Oct; 41(10):1379-85. PubMed ID: 26138283
[TBL] [Abstract][Full Text] [Related]
9. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal carcinomatosis: systematic review of clinical and experimental evidence with special emphasis on ovarian cancer.
Tempfer C; Giger-Pabst U; Hilal Z; Dogan A; Rezniczek GA
Arch Gynecol Obstet; 2018 Aug; 298(2):243-257. PubMed ID: 29869089
[TBL] [Abstract][Full Text] [Related]
10. No Renal Toxicity After Repeated Treatment with Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in Patients with Unresectable Peritoneal Metastasis.
Larbre V; Alyami M; Mercier F; Vantard N; Bonnefoy I; Opsomer MA; Villeneuve L; Bakrin N; Rioufol C; Glehen O; Kepenekian V
Anticancer Res; 2018 Dec; 38(12):6869-6875. PubMed ID: 30504403
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR).
Wimberger P; Lehmann N; Kimmig R; Burges A; Meier W; Du Bois A;
Gynecol Oncol; 2007 Jul; 106(1):69-74. PubMed ID: 17397910
[TBL] [Abstract][Full Text] [Related]
12. Correction to: The use of PIPAC (pressurized intraperitoneal aerosol chemotherapy) in gynecological oncology: a statement by the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Kommission Ovar, AGO Study Group, North-Eastern German Society of Gynaecologic Oncology (NOGGO), AGO Austria and AGO Switzerland.
Dueckelmann AM; Fink D; Harter P; Heinzelmann V; Marth C; Mueller M; Reinthaller A; Tamussino K; Wimberger P; Sehouli J
Arch Gynecol Obstet; 2018 Apr; 297(4):847. PubMed ID: 29445924
[TBL] [Abstract][Full Text] [Related]
13. Systemic chemotherapy and pressurized intraperitoneal aerosol chemotherapy (PIPAC): A bidirectional approach for gastric cancer peritoneal metastasis.
Di Giorgio A; Schena CA; El Halabieh MA; Abatini C; Vita E; Strippoli A; Inzani F; Rodolfino E; Romanò B; Pacelli F; Rotolo S
Surg Oncol; 2020 Sep; 34():270-275. PubMed ID: 32891341
[TBL] [Abstract][Full Text] [Related]
14. Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with Low-Dose Cisplatin and Doxorubicin in Gastric Peritoneal Metastasis.
Nadiradze G; Giger-Pabst U; Zieren J; Strumberg D; Solass W; Reymond MA
J Gastrointest Surg; 2016 Feb; 20(2):367-73. PubMed ID: 26511950
[TBL] [Abstract][Full Text] [Related]
15. Pressurized IntraPeritoneal Aerosol Chemotherapy - Practical aspects.
Hübner M; Grass F; Teixeira-Farinha H; Pache B; Mathevet P; Demartines N
Eur J Surg Oncol; 2017 Jun; 43(6):1102-1109. PubMed ID: 28431896
[TBL] [Abstract][Full Text] [Related]
16. Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.
du Bois A; Kristensen G; Ray-Coquard I; Reuss A; Pignata S; Colombo N; Denison U; Vergote I; Del Campo JM; Ottevanger P; Heubner M; Minarik T; Sevin E; de Gregorio N; Bidziński M; Pfisterer J; Malander S; Hilpert F; Mirza MR; Scambia G; Meier W; Nicoletto MO; Bjørge L; Lortholary A; Sailer MO; Merger M; Harter P;
Lancet Oncol; 2016 Jan; 17(1):78-89. PubMed ID: 26590673
[TBL] [Abstract][Full Text] [Related]
17. Intraperitoneal chemotherapy of peritoneal carcinomatosis using pressurized aerosol as an alternative to liquid solution: first evidence for efficacy.
Solass W; Kerb R; Mürdter T; Giger-Pabst U; Strumberg D; Tempfer C; Zieren J; Schwab M; Reymond MA
Ann Surg Oncol; 2014 Feb; 21(2):553-9. PubMed ID: 24006094
[TBL] [Abstract][Full Text] [Related]
18. [Protocol for the examination of surgical specimens from patients with peritoneal carcinomatosis originating in ovary, fallopian tube and peritoneum].
Medina Medina C; Gaona Morales J; Roselló-Sastre E; Delgado Barriga K; Escrig Sos J; Herráiz Roda JL; Llueca Abellá JA;
Rev Esp Patol; 2018; 51(4):216-223. PubMed ID: 30269772
[TBL] [Abstract][Full Text] [Related]
19. Low-dose pressurized intraperitoneal aerosol chemotherapy (PIPAC) as an alternative therapy for ovarian cancer in an octogenarian patient.
Giger-Pabst U; Solass W; Buerkle B; Reymond MA; Tempfer CB
Anticancer Res; 2015 Apr; 35(4):2309-14. PubMed ID: 25862894
[TBL] [Abstract][Full Text] [Related]
20. [Perioperative safety of intraperitoneal aerosol chemotherapy : Analysis of our first 111 pressurized intraperitoneal aerosol chemotherapy (PIPAC) procedures].
Jansen-Winkeln B; Thieme R; Haase L; Niebisch S; Pommer C; Lyros O; Zimmer J; Lordick F; Remane Y; Frontini R; Gockel I
Chirurg; 2019 Feb; 90(2):137-145. PubMed ID: 29947920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
